HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Robert M Sharkey Selected Research

Carcinoembryonic Antigen

1/2015Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients.
8/2012Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement.
1/2012Pretargeted immuno-PET of CEA-expressing intraperitoneal human colonic tumor xenografts: a new sensitive detection method.
11/2010Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice.
5/2010Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy.
4/2010Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts.
2/2008Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model.
9/2007Bispecific antibody pretargeting of radionuclides for immuno single-photon emission computed tomography and immuno positron emission tomography molecular imaging: an update.
4/2006Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group.
2/2006Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Robert M Sharkey Research Topics

Disease

66Neoplasms (Cancer)
12/2015 - 05/2002
15Non-Hodgkin Lymphoma (Lymphosarcoma)
11/2014 - 01/2003
8Colonic Neoplasms (Colon Cancer)
12/2012 - 09/2003
6Colorectal Neoplasms (Colorectal Cancer)
06/2015 - 05/2002
6Lymphoma (Lymphomas)
11/2014 - 01/2003
5Pancreatic Neoplasms (Pancreatic Cancer)
09/2015 - 01/2008
5Prostatic Neoplasms (Prostate Cancer)
02/2015 - 10/2011
3Carcinoma (Carcinomatosis)
06/2015 - 06/2008
2Adenocarcinoma
09/2015 - 06/2011
2Lung Neoplasms (Lung Cancer)
01/2015 - 02/2006
2Thyroid Neoplasms (Thyroid Cancer)
08/2012 - 04/2006
2Hematologic Neoplasms (Hematological Malignancy)
01/2012 - 05/2002
2Leukemia
01/2012 - 09/2008
2B-Cell Lymphoma (Lymphoma, B Cell)
10/2008 - 07/2008
1Diarrhea
09/2015
1Neutropenia
09/2015
1Stomach Neoplasms (Stomach Cancer)
05/2015
1Neoplasm Metastasis (Metastasis)
11/2014
1Hepatocellular Carcinoma (Hepatoma)
06/2013
1Inflammation
04/2010
1Burkitt Lymphoma (Burkitt's Lymphoma)
03/2009
1Glioblastoma (Glioblastoma Multiforme)
09/2006
1Glioma (Gliomas)
02/2006
1Body Weight (Weight, Body)
01/2003

Drug/Important Bio-Agent (IBA)

22AntibodiesIBA
01/2015 - 05/2002
17Carcinoembryonic AntigenIBA
01/2015 - 05/2002
16Radioisotopes (Radionuclides)IBA
01/2015 - 05/2002
14Immunoglobulin G (IgG)IBA
11/2015 - 05/2002
12AntigensIBA
02/2015 - 01/2003
7irinotecan (Camptosar)FDA LinkGeneric
11/2015 - 01/2012
6Bispecific AntibodiesIBA
02/2015 - 05/2002
6Immunoconjugates (Immunoconjugate)IBA
01/2015 - 11/2003
5DOTA- tyrosyl- lysyl(histaminyl- succinyl- glycyl)- glutamyl- lysyl(histaminyl- succinyl- glycyl)amideIBA
02/2015 - 04/2010
5Histamine (Histamine Dihydrochloride)FDA Link
12/2009 - 11/2005
5Glycine (Aminoacetic Acid)FDA LinkGeneric
12/2009 - 11/2005
4PeptidesIBA
02/2015 - 01/2003
3MucinsIBA
09/2015 - 12/2009
3monoclonal antibody IMMU-106IBA
11/2014 - 10/2008
3Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
01/2012 - 10/2006
3hLL2 agent (epratuzumab)IBA
01/2012 - 12/2003
3Monoclonal AntibodiesIBA
06/2011 - 11/2003
2gemcitabineFDA Link
09/2015 - 12/2009
2YttriumIBA
09/2015 - 01/2003
2labetuzumabIBA
06/2015 - 09/2003
2Biotin (Vitamin H)FDA Link
01/2015 - 02/2006
2procaine isothiocyanate (PRIT)IBA
09/2013 - 11/2010
2Pentetic Acid (DTPA)FDA LinkGeneric
02/2010 - 01/2003
2Inosine Monophosphate (IMP)IBA
06/2009 - 05/2004
2Immunoglobulin Fab FragmentsIBA
05/2006 - 10/2005
2Proteins (Proteins, Gene)IBA
01/2004 - 09/2003
1Membrane Glycoproteins (Membrane Glycoprotein)IBA
09/2015
1bevacizumabFDA Link
06/2015
1Type I DNA Topoisomerases (Topoisomerase I)IBA
06/2015
1Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
05/2015
1CaspasesIBA
05/2015
1AvidinIBA
01/2015
1Doxorubicin (Adriamycin)FDA LinkGeneric
06/2013
1milatuzumabIBA
06/2013
1Calcitonin (Calcitonin, Eel)FDA LinkGeneric
08/2012
1Immunoglobulin FragmentsIBA
06/2012
1Staphylococcal Protein A (A, Protein)IBA
10/2011
1Glycoproteins (Glycoprotein)IBA
06/2011
1First StepIBA
06/2010
1Somatostatin Receptors (Somatostatin Receptor)IBA
03/2010
11,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)IBA
06/2009
1triazacyclononaneIBA
06/2009
1Annexin A5IBA
04/2009
1peptide 74IBA
03/2009
1FluorineIBA
02/2008
1Fibronectins (Fibronectin)IBA
09/2006
1StreptavidinIBA
02/2006
1Recombinant ProteinsIBA
02/2006
1rituximab (Mabthera)FDA Link
05/2004
1Indicators and Reagents (Reagents)IBA
01/2004
1IsotopesIBA
11/2003
1HaptensIBA
09/2003
1ibritumomab tiuxetan (Zevalin)FDA Link
06/2003
1Tuberculin (PPD)IBA
01/2003
1Chelating AgentsIBA
01/2003
1Surface Antigens (Surface Antigen)IBA
05/2002

Therapy/Procedure

35Radioimmunotherapy
12/2015 - 05/2002
26Heterologous Transplantation (Xenotransplantation)
11/2015 - 01/2003
4Drug Therapy (Chemotherapy)
09/2015 - 01/2003
2Therapeutics
09/2012 - 06/2010
1Drug Substitution
06/2015
1Injections
01/2015
1Computer-Assisted Surgery (Image Guided Surgery)
11/2014
1Stem Cell Transplantation
11/2014
1Radiotherapy
09/2006
1Immunotherapy
07/2006